Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Recruiting · NCT06919939 · Registry updated 2026-03-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Relapse, large B-cell lymphoma | Recruiting | Phase 2 | 2026-03-02 | NCT06919939 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ADC Therapeutics S.A. | 12 |
| Genmab | 54 |
| University of Miami | 277 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Miami | Miami | United States | 327 |